Functional MRI (fMRI) applications developer Neurognostics has received 510(k) market clearance from the U.S. Food and Drug Administration for its MindState functional data acquisition device (fDAD).
The product enables healthcare professionals to acquire fMRI data that may be used to track disease progression in patients with central nervous system disorders. The device can also be used to test drug efficacy, according to the Milwaukee-based company.
By AuntMinnie.com staff writers
February 2, 2005
Related Reading
Road to RSNA, Neurognostics, November 18, 2004
Functional MRI: Advancing clinical opportunities for neuroradiology, November 8, 2004
Neurognostics sees business potential in fMRI, November 1, 2004
Copyright © 2005 AuntMinnie.com
.fFmgij6Hin.png?auto=compress%2Cformat&fit=crop&h=100&q=70&w=100)
.fFmgij6Hin.png?auto=compress%2Cformat&fit=crop&h=167&q=70&w=250)
